HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease.

Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disorder marked by cell death in the Substantia nigra (SN). Docosahexaenoic acid (DHA) is the major polyunsaturated fatty acid (PUFA) in the phospholipid fraction of the brain and is required for normal cellular function. Glial cell line derived neurotrophic factor (GDNF) and neurturin (NTN) are very potent trophic factors for PD. The aim of the study was to evaluate the neuroprotective effects of GDNF and NTN by investigating their immunostaining levels after administration of DHA in a model of PD. For this reason we hypothesized that DHA administration of PD might alter GDNF, NTN expression in SN. MPTP neurotoxin that induces dopaminergic neurodegeneration was used to create the experimental Parkinsonism model. Rats were divided into; control, DHA-treated (DHA), MPTP-induced (MPTP), MPTP-induced+DHA-treated (MPTP+DHA) groups. Dopaminergic neuron numbers were clearly decreased in MPTP, but showed an increase in MPTP+DHA group. As a result of this, DHA administration protected dopaminergic neurons as shown by tyrosine hydroxylase immunohistochemistry. In the MPTP+DHA group, GDNF, NTN immunoreactions in dopaminergic neurons were higher than that of the MPTP group. In conclusion, the characterization of GDNF and NTN will certainly help elucidate the mechanism of DHA action, and lead to better strategies for the use of DHA to treat neurodegenerative diseases.
AuthorsGamze Tanriover, Yasemin Seval-Celik, Ozlem Ozsoy, Gokhan Akkoyunlu, Feyza Savcioglu, Gulay Hacioglu, Necdet Demir, Aysel Agar
JournalFolia histochemica et cytobiologica / Polish Academy of Sciences, Polish Histochemical and Cytochemical Society (Folia Histochem Cytobiol) Vol. 48 Issue 3 Pg. 434-41 (Sep 30 2010) ISSN: 1897-5631 [Electronic] Poland
PMID21071351 (Publication Type: Comparative Study, Evaluation Studies, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Glial Cell Line-Derived Neurotrophic Factor
  • Neuroprotective Agents
  • Neurotoxins
  • Neurturin
  • Docosahexaenoic Acids
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Tyrosine 3-Monooxygenase
  • Dopamine
Topics
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Animals
  • Disease Models, Animal
  • Docosahexaenoic Acids (pharmacology)
  • Dopamine (metabolism)
  • Glial Cell Line-Derived Neurotrophic Factor (adverse effects, metabolism, pharmacology)
  • Immunohistochemistry
  • Male
  • Nerve Degeneration (chemically induced, pathology)
  • Neurons (drug effects)
  • Neuroprotective Agents (pharmacology)
  • Neurotoxins
  • Neurturin (adverse effects, metabolism, pharmacology)
  • Parkinson Disease, Secondary (pathology)
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Substantia Nigra (cytology, metabolism, pathology)
  • Tyrosine 3-Monooxygenase (immunology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD